Literature DB >> 23289697

Questions concerning the clinical translation of cell-based interventions under an innovation pathway.

Jeremy Sugarman1.   

Abstract

Stem cell-based innovation is one pathway to clinical translation that stands in contrast to clinical research and medical treatment. After reviewing recently issued guidelines for responsible innovation, this article examines the potential benefits and harms of using this pathway as well as practical barriers and conceptual concerns regarding it.
© 2012 American Society of Law, Medicine & Ethics, Inc.

Mesh:

Year:  2012        PMID: 23289697     DOI: 10.1111/j.1748-720X.2012.00723.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  4 in total

1.  Ethics and policy issues for stem cell research and pulmonary medicine.

Authors:  Justin Lowenthal; Jeremy Sugarman
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

Review 2.  Ethical considerations in tissue engineering research: Case studies in translation.

Authors:  Hannah B Baker; John P McQuilling; Nancy M P King
Journal:  Methods       Date:  2015-08-14       Impact factor: 3.608

3.  Innovative Practice, Clinical Research, and the Ethical Advancement of Medicine.

Authors:  Jake Earl
Journal:  Am J Bioeth       Date:  2019-06       Impact factor: 11.229

4.  Cell-based interventions in utero: time to reconsider.

Authors:  Nancy M P King; Ana S Iltis
Journal:  Front Pharmacol       Date:  2014-09-17       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.